Forecyte Bio opened its brand-new, state-of-the-art cell and gene therapy GMP facility in Shanghai, China following the opening of its US facility in January.

The 140,000-square-foot facility, with a price tag of nearly $40 million, offers multiple GMP production lines for plasmids, viral vectors, and cell therapies. The dual sites in the US and China offer advantages to cell and gene therapy (CGT) companies, especially those to file internationally.

Both facilities offer high-quality production capacities operated by industry veterans and an executive team experienced in CGT CMC manufacturing. Forecyte Bio's 4x4 holistic approach covers a wide range of the CGT CMC workflow.

Through its high-quality, efficient and agile services, Forecyte Bio helps its customers to accelerate their product development process from R&D to clinic and to the market, and at the same time enables cell and gene therapy products to be manufactured and filed in multiple nations.